In recent years, researchers have explored the potential of DYRK1A and DYRK1B inhibitors as therapeutic agents for activating pancreatic β-cell growth and ultimately treating T1D; however, pancreatic β cell expansion was a challenge due to their low proliferative ability (Gregg et al., 2012; Meier et al., 2008). This evidence concerns the gene DYRK1A and type 1 diabetes mellitus.